543
Views
1
CrossRef citations to date
0
Altmetric
Editorial Article

Ifosfamide in Sarcomas: Is It a Schedule-Dependent Drug?

&
Pages 290-291 | Published online: 11 Jun 2009

References

  • Benjamin R S, Legha S S, Patel S R, et al. Ifosfamide studies in sarcomas: The M. D. Anderson Experience. Cancer Chemother Pharmacol 1993; 31(Suppl 2)S174–179
  • Chawla S P, Rosen G, Lowenbraun S, et al. High-dose ifosfamide therapy in metastatic soft-tissue sarcoma. Proc Am Assoc Cancer Res 1990; 31: 198, (abstract 1175)
  • Brian E, Le Cesne A, Le Chevallier T, et al. High-dose ifosfamide can circumvent resistance to standard dose ifosfamide in advanced soft-tissue sarcomas. Proc Am Soc Clin Oncol 1993; 12: 470, (abstract 1641)
  • Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma: Uniform response to high-dose ifosfamide. Cancer 1994; 73(10)2506–2511
  • Patel S R, Vadhan-Raj S, Trevino C, et al. Phase II study of high dose ifosfamide + G-CSF in patients with malignant bone tumors and metastatic soft-tissue sarcomas. Proc Am Soc Clin Oncol 1992; 11: 413, (abstract 1448)
  • Patel S R, Hays C, Papadopoulos N E, et al. Pilot study of high-dose ifosfamide + G-CSF in patients with bone and soft-tissue sarcomas. Proc Am Soc Clin Oncol 1995; 14: 516, (abstract 1691)
  • Antman K, Ryan L, Elias A, et al. Response to ifosfamide and Mesna: 124 previously treated patients with metastatic or unresectable sarcoma. J Clin Oncol 1989; 1: 126–131

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.